Last reviewed · How we verify
Fluzone inactivated influenza vaccine
At a glance
| Generic name | Fluzone inactivated influenza vaccine |
|---|---|
| Sponsor | Richard Zimmerman MD |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- COVID-19 Booster and IIV Schedule in Immunocompromised Hosts (PHASE2)
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (PHASE1)
- Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |